Hematopoietic Cell Transplantation, Version 3.2022 Featured Updates to the NCCN Guidelines

The NCCN Guidelines for Hematopoietic Cell Transplantation (HCT) provide an evidence-and consensus-based approach for the use of au-tologous and allogeneic HCT in the management of malignant dis-eases in adult patients. HCT is a potentially curative treatment option for patients with certain types of malignancies; however, recurrent ma-lignancy and transplant-related complications often limit the long-term survival of HCT recipients. The purpose of these guidelines is to provide guidance regarding aspects of HCT, including pretransplant recipient evaluation, hematopoietic cell mobilization, and treatment of graft-versus-host disease-a major complication of allogeneic HCT- to enable the patient and clinician to assess management options in the context of an individual patient's condition. These NCCN Guide-lines Insights provide a summary of the important recent updates to the NCCN Guidelines for HCT, including the incorporation of a newly developed section on the Principles of Conditioning for HCT.J Natl Compr Canc Netw 2023;21(2):108-115doi: 10.6004/jnccn.2023.0007

Automated summary

The NCCN Guidelines provide evidence-based recommendations for hematopoietic cell transplantation in adult patients with malignant diseases. These guidelines cover various aspects of transplantation, including recipient evaluation, cell mobilization, and treatment of graft-versus-host disease, aiming to assist patients and clinicians in making informed decisions.